Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия
Список исп. литературыСкрыть список 1. FDA Office of Surveillance and Epidemiology. Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM 277384.pdf 2. Brandt ML, Luks FI, Filiatrault D et al. Surgical indications in antenatally diagnosed ovarian cysts. J Pediatr Surg 1991; 26: 276. 3. Диагностика и лечение доброкачественных новообразований яичников с позиции профилактики рака. Клинические рекомендации (протокол лечения) 2018 г. М., 2018. [Diagnostika i lechenie dobrokachestvennykh novoobrazovanii iaichnikov s pozitsii profilaktiki raka. Klinicheskie rekomendatsii (protokol lecheniia) 2018. Moscow, 2018 (in Russian).] 4. Myers ER, Bastian LA, Havrilesky LJ et al. Management of Adnexal Mass. Evidence Report/Technology Assessment №130 (Prepared by the Duke Evidence-based Practice Center under Contract №290-02-0025). AHRQ Publication №06-E004, Agency for Healthcare Research and Quality, Rockville, MD February 2006. 5. Brown DL, Doubilet PM, Miller FH et al. Benign and malignant ovarian masses: selection of the most discriminating gray-scale and Doppler sonographic features. Radiology 1998; 208: 103. 6. Tailor A, Jurkovic D, Bourne TH et al. Sonographic prediction of malignancy in adnexal masses using multivariate logistic regression analysis. Ultrasound Obstet Gynecol 1997; 10: 41. 7. Van Calster B, Van Hoorde K, Valentin L et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ 2014; 349: g5920. 8. http://seer.cancer.gov/ (Accessed on September 07, 2012). 9. Im SS, Gordon AN, Buttin BM et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005; 105: 35. 10. Buys SS, Partridge E, Greene MH et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005; 193: 1630. 11. Jacobs IJ, Menon U, Ryan A et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016; 387: 945. 12. Committee on Health Care for Underserved Women. Committee opinion no. 615: Access to contraception. Obstet Gynecol 2015; 125: 250. Reaffirmed 2017. 13. Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007; 335: 651. 14. Management of Suspected Ovarian Masses in Premenopausal Women. RCOG/BSGE Joint Green-top Guideline 2011; 62. 15. Grimes DA, Jones LB, Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev 2014; 4: CD006134. 16. Taskin O, Young DC, Mangal R, Aruh I. Prevention and treatment of ovarian cysts with oral contraceptives: a prosepctive randomized study. J Gynecol Surg 1996; 12: 21. 17. Biljan MM, Mahutte NG, Dean N et al. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues. J Assist Reprod Genet 1998; 15: 599. 18. Raziel A, Ron-El R, Pansky M et al. Current management of ruptured corpus luteum. Eur J Obstet Gynecol Reprod Biol 1993; 50: 77. 19. Kim JH, Lee SM, Lee JH et al. Successful conservative management of ruptured ovarian cysts with hemoperitoneum in healthy women. PLoS One 2014; 9: e91171. 20. Yian MT, Chen HJ, Chu TY, Yin CS. Postcoital hemoperitoneum without identifiable bleeding source: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 1996; 58: 291. 21. Mandato VD, Pirillo D, Ciarlini G et al. Postcoital haemperitoneum without vaginal injury, a clinical challenge. Aust N Z J Obstet Gynaecol 2010; 50: 580. 22. McColgin SW, Williams LM, Sorrells TL, Morrison JC. Hemoperitoneum as a result of coital injury without associated vaginal injury. Am J Obstet Gynecol 1990; 163: 1503. 23. Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care 2008; 34: 237. 24. Holt VL, Cushing-Haugen KL, Daling JR. Oral contraceptives, tubal sterilization, and functional ovarian cyst risk. Obstet Gynecol 2003; 102: 252. 25. Holt VL, Daling JR, McKnight B et al. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol 1992; 79: 529. 26. van Heusden AM, Fauser BC. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception 1999; 59: 237. 27. Spanos WJ. Preoperative hormonal therapy of cystic adnexal masses. Am J Obstet Gynecol 1973; 116: 551. 28. Functional ovarian cysts and oral contraceptives. Negative association confirmed surgically. A cooperative study. JAMA 1974; 228: 68. 29. Caillouette JC, Koehler AL. Phasic contraceptive pills and functional ovarian cysts. Am J Obstet Gynecol 1987; 156: 1538. 30. Mishell DR Jr. Noncontraceptive benefits of oral contraceptives. J Reprod Med 1993; 38: 1021. 31. Grimes DA, Godwin AJ, Rubin A et al. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet Gynecol 1994; 83: 29. 32. Egarter C, Putz M, Strohmer H et al. Ovarian function during low-dose oral contraceptive use. Contraception 1995; 51: 329. 33. US Food and Drug Administration. Birth Control Pills Containing Drospirenone: Label Change-Products may be associated with a higher risk for blood clots. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm299605.htm (Accessed on April 17, 2016) 34. Willis SA, Kuehl TJ, Spiekerman AM et al. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006; 74: 100–3.